Submitted by Anonymous (not verified) on 11 August 2023 - 10:13
Human medicines European public assessment report (EPAR): Trodelvy, sacituzumab govitecan, Breast Neoplasms;Triple Negative Breast Neoplasms, Date of authorisation: 22/11/2021, Revision: 3, Status: Authorised
Source: